51 PERIMENOPAUSE SYMPTOMS. YOUR DOCTOR KNOWS 5.

// BLUNTBIRDS REPORT //

Reported by // Special Agents // Georgie F. & Aubrey R.

Unit // BluntBirds // Intelligence Division

// Classification // [H.Q.] Approved for Public Access]

TRANSMISSION RECEIVED: March 26, 2026

// TRANSMISSION START //

⚠️ CRITICAL INTEL DISCLAIMER ⚠️

This report documents 51 physiological presentations of perimenopause currently logged in the EVE Directive data archive and the medical training gap that means the person you are most likely to see about them has received approximately one hour of formal education on the subject. In some cases limited to a single lecture or module.

We wish we were joking. We're not.

This is not a wellness blog. This is field intelligence documenting what medical institutions failed to study and what the curriculum failed to teach, and why both of those failures are still, right now, being felt in every consultation room where a woman sits down and tries to describe something that the person across from her was never trained to hear.

Bullshit filters: removed. BluntBird surgical precision: applied.

This is not opinion. It's recon.

Contents classified as: REBELLIOUSLY ACCURATE.

Before we go any further, an analogy. Because the number alone does not quite capture the institutional texture of what produced it.

Imagine you are boarding a commercial flight and you discover that your pilot received one hour of training on how to operate the aircraft.

Not one hour per system. Not one hour per emergency procedure.

One hour. Total.

With everything beyond that dependent on whatever workshops they had chosen to attend in their own time, if they got around to it, around the demands of a full schedule.

You would not board that flight.

You would, in fact, immediately deplane, file a complaint, and spend the next forty-five minutes on hold with the aviation authority. Because the idea of sending an undertrained person into a complex, dynamic system without adequate preparation is so obviously unacceptable that it barely qualifies as a hypothetical.

And yet, here we are.

Welcome to the women's jungle.

That analogy maps with uncomfortable precision onto the formal preparation that a newly qualified GP receives for perimenopause: a biological transition that can affect the brain, the cardiovascular system, the nervous system, sleep architecture, inflammatory response, metabolic function, and hormonal regulation simultaneously, in approximately half the global population, for up to a decade.

The pilots get forty hours minimum and are then required to complete ongoing recurrency training to maintain their licence. The Civil Aviation Safety Authority, for what it's worth, does not accept "have you tried chamomile" as a navigational aid under any weather conditions.

General practitioners may receive only minimal formal education on menopause during their initial training, in some programs reported as a single lecture or module, with further learning left to voluntary continuing education.

The Royal Australian College of General Practitioners confirms the gap is real and the additional training largely optional. In the United Kingdom, the pattern holds: a 2022 survey found that many GPs had received no formal menopause training during their GP education at all, and the Royal College of General Practitioners recently argued against mandating that training, placing the responsibility on individual doctors to keep themselves current voluntarily, in their own time, around a full patient load.

When Dr. Mary Jane Minkin, OB-GYN and clinical professor at Yale School of Medicine, was asked how much time she receives to teach medical students about menopause during their entire OB-GYN rotation, her answer was one hour. She said she would love to teach them more. The curriculum does not allocate the time. ¹ ²

Public-facing guidance on perimenopause tends to centre on a narrow cluster of symptoms, most commonly hot flushes, mood changes, and menstrual irregularity. The EVE Directive archive currently logs 51 documented presentations (and counting). That cluster, real and widely experienced as it is, represents roughly the equivalent of a pilot's training covering takeoff, landing, and the seatbelt sign. The other things the plane does were apparently optional reading.

Those other documented presentations include brain fog severe enough that women are referred for dementia screening. Joint pain that arrives overnight with no prior history. Heart palpitations diagnosed as anxiety. Tinnitus. Paresthesia, reported by patients as electric shock or tingling sensations under the skin, documented globally, reported consistently, and classified in too many clinical records as "unexplained" rather than "under-researched."

Reports also indicate that some women experience changes in how ADHD symptoms present during perimenopause, including reduced reliability of previously effective treatments.

A 2025 systematic review found the evidence base on ADHD and female sex hormones remains limited and concentrated primarily on puberty and the menstrual cycle, with menopause-specific research still lacking. ³

Similarly, autistic burnout during perimenopause has, in some cases, been misclassified as personality disorder — the visible consequence of a coping system collapsing under hormonal pressure in individuals whose underlying neurology was never recognised within the same system.

// HISTORICAL FIELD ANALYSIS //

BY: SPECIAL AGENT GEORGIE FOXGLOVE

// SUBJECT: How The Research Void Was Built

In our first transmission, we traced the diagnostic impulse: the literally thousands-year habit of locating the problem inside the woman rather than in the system observing her, or dismissing her from the equation entirely. If you have not read it, it is in the archive. It ends with the observation that the language changed but the mechanism did not. This transmission picks up where that one left off, because what happened next is the specific chain of decisions that produced the one-hour curriculum, and it is not ancient history.

It is 1977.

The United States Food and Drug Administration issued guidance that year formally excluding women of childbearing potential from early-stage clinical trials. The stated rationale was fetal protection, liability management, and the inconvenient complexity of the menstrual cycle as a variable, a biological reality so burdensome to researchers that half the human population was simply removed from the data rather than accommodated within it.

The guidance was in place from 1977 to 1993. Sixteen years during which the research establishing drug safety, metabolic tolerances, dosing parameters, and our foundational clinical understanding of how diseases present was conducted almost entirely on male subjects and then applied universally to female patients as though the two physiologies were interchangeable. They are not interchangeable. This was not a secret. It was treated as an acceptable variable to control.

The FDA reversed the policy in 1993. The knowledge deficit it created did not reverse with it. The drugs approved during those sixteen years, many of which are still prescribed today, retain dosing guidelines derived from the male physiology on which they were tested. The diagnostic criteria in current clinical use were built from research that treated female biology as a complexity to exclude rather than a population too significant to ignore. The training gap that produces a GP with one hour of menopause education is, in part, the downstream consequence of a sixteen-year period during which the research that would have informed that training was not conducted.

// FU*#ED FACTS WITH GEORGIE //

In 2002, the Women's Health Initiative published findings that a particular combined formulation of hormone therapy was associated with a modestly elevated risk of breast cancer, heart attack, and stroke in a specific postmenopausal cohort. Global prescriptions for hormone therapy dropped sharply. Clinical interest in menopausal medicine contracted. Research funding followed. The curriculum, already thin, had even less underpinning it.

What subsequent research has established, progressively and clearly over the two decades since, is that the WHI findings were specific to a particular population, a particular formulation, and a particular timing window, and that applying them universally to all women, all formulations, and all stages of the menopausal transition was not supported by the original study design. The limitations were documented. A 2025 editorial in Nature described researchers and clinicians as still, more than twenty years later, researchers and clinicians are still correcting how those findings were interpreted ⁴

The contraction of interest and funding that followed the 2002 publication persisted well beyond the point at which the evidence had been substantially refined.

The women who needed that information in 2002, and 2005, and 2010, navigated a decade-long transition using clinical guidance shaped by a study the field had already moved past. They were not told this. Analyses of NIH-funded grants during this same period have shown substantially greater research attention directed toward pregnancy than menopause. In one 2019 analysis, more than 300 grant titles included the word "pregnancy" against 28 that included "menopause." ⁵

Menopause has historically received limited dedicated tracking within major research funding portfolios, despite being a universal biological transition for half the global population.

This is the architecture behind the woeful lack of training, or obligations to acquire such training as vital curriculum. It was not built carelessly.

It was built from a series of decisions, made across institutions, over decades, each of which made a certain kind of institutional sense in isolation and produced, in accumulation, a medical system that sends a doctor into a consultation about a decade-long hormonal transition with sixty minutes of preparation and a brochure covering a handful of symptoms that not all women experience in equal measure- or sometimes even at all.

The women arriving at diagnoses through TikTok comment sections at two in the morning are not a failure of public health literacy. They are the logical endpoint of a research architecture that was never built to find them. Their frantic frustrations and social media rants of anger and desperation are vast and resonant across the global jungle floor.

"Whether it's hormonally liberated rage or not, I'd say they're allowed to be a little pissed off. Women and their anger is not the problem. It's centuries of missing data."

// JOINT ANALYSIS //

SPECIAL AGENTS: GEORGIE F. & AUBREY R.

// What Is Actually Happening Biologically, And Why The Curriculum Gap Made It Invisible //

Perimenopause is not a single hormonal event but a sustained and unpredictable transition phase, typically beginning in a woman's late 30s to mid-40s, during which estrogen and progesterone do not decline in any orderly or predictable fashion. Hormone levels fluctuate dramatically across weeks and months, spiking, crashing, and destabilising again in patterns that vary significantly between individuals and bear little resemblance to the gradual taper that the word "transition" implies.

What makes this clinically significant beyond the familiar triad of symptoms that made the brochure, that is hot flashes, irregular cycles and mood disruption, is the breadth of physiological systems that estrogen regulates, and which most clinical training has not adequately prepared practitioners to connect to hormonal fluctuation in mid-life women. Estrogen modulates the availability and activity of dopamine, serotonin, and acetylcholine, three neurotransmitters central to cognitive function, mood regulation, and memory consolidation.

Emerging evidence suggests that hormonal shifts can affect ADHD symptom burden and medication response in some women, but menopause-specific research remains limited. A 2025 systematic review found the evidence base was small and concentrated mainly on puberty and the menstrual cycle, and called for more investigation into menopause specifically.³

A follow-up survey study from the same research group, published in the Journal of Psychiatric Research in 2026, documented that women with ADHD consistently reported significant worsening of symptoms across hormonal life stages — including perimenopause — yet the clinical frameworks to address this remain largely absent. ⁶

This is not fringe science. It has been in the peer-reviewed literature for over a decade. It simply has not made it consistently into the curriculum.

The practical consequence for women managing ADHD with stimulant medication is specific and often devastating. Stimulant medications work, in part, by increasing dopamine availability in the prefrontal cortex.

Estrogen also modulates dopamine availability through its effects on receptor density and reuptake mechanisms. When estrogen becomes erratic during perimenopause, the neurochemical environment that the medication was calibrated against no longer exists in a stable or predictable form, and a drug that had structured someone's executive function for years begins to fail.

Not because the diagnosis was wrong. Not because the dosage has become inadequate on its own terms. Because the hormonal substrate it depended on has fundamentally shifted.

The clinical setting those women arrive in has, statistically, received approximately 70 seconds of theoretical preparation per documented perimenopause symptom, the arithmetic of one hour divided across 51 presentations. What they frequently receive instead of a biological explanation is a notation suggesting drug-seeking behaviour. That is the distance between what the evidence shows and what the training provides.

// The Autism Intersection, And Why It Requires Its Own Context

The intersection with autism involves a different but equally consequential mechanism, and one that requires some framing, because the clinical concept at its centre is widely misunderstood outside autistic experience, and that misunderstanding has its own history of causing harm in exactly the kinds of clinical settings we are examining here.

Autistic people, particularly women, frequently develop highly sophisticated adaptive strategies for navigating social and professional environments that were not designed for the way their nervous systems process the world. This is not performance in the theatrical sense, and it is not deception. It is the result of years, often decades beginning in early childhood, of learning, consciously and unconsciously, which behaviours, responses, and ways of presenting are socially legible to neurotypical people, and deploying them in order to function in systems that were built without them in mind. Researchers and clinicians in this field refer to this as masking. What the evidence has established is that it is metabolically and cognitively expensive in ways that most neurotypical people do not have an intuitive framework for understanding, not because it is beyond comprehension, but because it is not part of their daily experience and has rarely been explained to them at any point in their education or training.

Critically, many autistic women are not fully aware that they are doing it. For those diagnosed in adulthood, a pattern particularly common among women whose autistic presentations were historically excluded from the diagnostic criteria built almost entirely on research conducted with young boys, the realisation that this adaptive process has been operating underneath their apparent functioning for their entire lives frequently arrives alongside the diagnosis itself, and sometimes well after it. The cognitive load was real the entire time. The effort was real the entire time. It simply had no name in the systems that were supposed to be looking for it.

This matters for perimenopause because masking draws heavily on executive function, working memory, and sustained cognitive regulation, the same systems that estrogen fluctuation disrupts. When perimenopause begins competing for the neurological resources required to sustain these adaptive strategies, the result is not a new condition emerging but the withdrawal of a coping mechanism that was always metabolically costly and has now become, under hormonal pressure, unsustainable. Across multiple healthcare systems, the resulting presentation has in some cases been misclassified as personality disorder, a diagnostic category applied to the visible consequence of something the treating clinician had no training to identify as a hormonal presentation, in someone whose underlying neurology had never been recognised or supported by the same system in the first place.

A considerably deeper investigation into this intersection is in a dedicated transmission. For now, the mechanism is the point.

// THE EVE DIRECTIVE DATA ARCHIVE //

// 51. And Counting. //

The 51 presentations currently logged in the EVE archive are not the final count. They are the current count from a catalogue being built precisely because the institutional structures that should have built it consistently directed their attention elsewhere. The archive is still building.

The public health guidance was not wrong about hot flushes, irregular cycles, or mood changes. They are real, documented, and widely experienced. What failed was the implication that this narrow cluster constituted an adequate account of what a decade-long transition involving every major physiological system actually contains. The GP sitting across from you was not necessarily wrong to be uncertain. They may have been working from a textbook that had less than a paragraph, following training that received minimal curriculum space, operating inside a research funding landscape that has historically given substantially more attention to other conditions than to this one.

The people who were wrong are not in the consultation room.

That is where this investigation is going. The surface, documented above, is sufficient to establish that the right questions are finally being asked. The archive is building. We are not stopping.

// FINAL REMARKS //

Strap yourselves in, petals.

Episode 3 has dropped.

The next transmissions are already in the field. The layers underneath what we have documented today, who decided what gets funded, who maintained the curriculum, what the research that does exist is quietly telling us about what was always known and never prioritised, are where this goes next.

You are going to want to stay inside the signal buffer for this one.

// GEORGIE & AUBREY OUT //

// TRANSMISSION ENDS //

[H.Q]

// BECOME PART OF SOMETHING YOU DESERVE. //

// SOURCES //

¹ Dr. Mary Jane Minkin, OB-GYN, Yale School of Medicine. Reported in "Wise Women — Why Menopause Matters" documentary/interview, 2025.

² Allen, J. et al. "Needs assessment of menopause education in United States OB-GYN residency programs." Menopause, 2023. pubmed.ncbi.nlm.nih.gov/37738034

³ Osianlis, E. et al. "ADHD and Sex Hormones in Females: A Systematic Review." Journal of Attention Disorders, 2025. Evidence base limited; majority of studies focus on puberty and menstrual cycle, with menopause-specific research lacking.

⁴ Nature Editorial. "Menopause research is globally underfunded. It's time to change that." January 2025.

(Referencing original WHI findings: Women's Health Initiative Writing Group, JAMA, 2002.)

⁵ PMC. "Menopause preparedness: perspectives for patient, provider and policymaker consideration." NIH funding disparity analysis, 2019 data. pmc.ncbi.nlm.nih.gov/articles/PMC8462440

⁶ Barth, C. et al. "Sex hormones affect neurotransmitters and shape the adult brain during hormonal transition periods." Frontiers in Neuroscience, 2015.

⁷ UCL Commentary. Dr. Megan Arnot, 2023. Includes analysis of global medical textbook content (58% no menopause reference; 12% minimal coverage).

⁸ Australian Government Department of Health. "Strengthening Medicare with over $500 million for women's health." February 2025. health.gov.au

Monash University analysis, 2025.

⁹ UK GP survey on menopause training and satisfaction with NICE guidelines. PMC, 2022. pmc.ncbi.nlm.nih.gov/articles/PMC9500171